Related Experiment Video
Updated: Jul 6, 2026

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
Published on: June 26, 2013
Association Between Glymphatic Dysfunction and Anxiety in Parkinson's Disease: Insights from DTI-ALPS and Choroid
Lu Sa1, Shan Li2, Linyu Chen3
1Department of MRI, the First People's Hospital of Yunnan Province, the Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, 650032, People's Republic of China.
Purpose:
To explore glymphatic system function in Parkinson's disease (PD) patients with anxiety using multimodal imaging: diffusion tensor image analysis along the perivascular space (DTI-ALPS), enlarged perivascular space (EPVS) number, and choroid plexus volume (CPV).
Patients And Methods:
In this prospective observational study, 64 PD patients (34 with anxiety [PD-A] and 30 without anxiety [PD-NA]) and 42 healthy controls (HC) were recruited. All participants underwent clinical assessments for anxiety, depression, cognition, and motor symptoms. DTI-ALPS index, EPVS number, and CPV were compared among the three groups, and a composite model integrating these multimodal metrics was developed.Additionally,a partial correlation analysis was conducted to investigate the relationship between the above three imaging indicators and clinical characteristics in PD-A.
Results:
Compared to the PD-NA, DTI-ALPSr (P =0.047) and DTI-ALPSb (P =0.01)decreased, and CPVl (P =0.046) increased in PD-A group. DTI-ALPS index was negatively correlated with CPV in PD patients.Based on receiver operating curve (ROC) analysis, the Top Single-Markers model demonstrated superior efficacy in discriminating PD from HC (AUC =0.847). Furthermore, a composite model showed predictive value for anxiety in PD (AUC =0.748). After controlling for age, gender, and education, CPV was correlated positively with Hamilton Anxiety Rating Scale (HAM-A) (r =0.657, P =0.031) and Non-Motor Symptom Scale(NMSS) (r =0.617, P =0.041).Standardized CPV was correlated negatively with Montreal Cognitive Assessment (MoCA) (r =-0.640, P =0.034) and Unified Parkinson's Disease Rating Scale III (UPDRS III) (r =0.659, P =0.03).
Conclusion:
PD patients exhibit cerebral glymphatic dysfunction, which is more severe in those with anxiety. Increased CPV is associated with anxiety, depression, and cognitive decline in PD-A patients. Combining multimodal MRI metrics shows potential clinical utility for evaluating glymphatic function.
Trial Registration Number:
NCT06858176.
Related Concept Videos
Neural Regulation
Parkinson's Disease: Overview
Parkinson Disease l: Introduction
Parkinson Disease ll: Pathophysiology
Alterations in Muscle Tone lll

